Octreotide Hospira

Octreotide, the active ingredient in Octreotide Hospira, is a peptide synthetic analogue of somatostatin presented as a formulation for injectable use. It regulates hormone secretion and is used in the management of certain endocrine disorders and tumor‑related conditions in adults.

GNH USA supplies Octreotide Hospira as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and oncology centres worldwide.

Octreotide Hospira is a synthetic somatostatin analogue that modulates neuroendocrine activity in several disease pathways. - Acromegaly: helps reduce excess growth‑hormone secretion, improving clinical signs. - Neuroendocrine tumors (carcinoid syndrome): controls flushing and diarrhoea by inhibiting vasoactive peptide release. - Preventing postoperative pancreatic fistula: reduces pancreatic secretions after major abdominal surgery. - Control of severe refractory diarrhoea associated with vaso‑vascular tumors. - Management of hypoglycaemia related to insulinoma or beta‑cell hyper‑activity. - Symptom relief in carcinoid‑related bronchial obstruction of the air ways

Octreotide may produce a range of adverse reactions, most of which are dose‑dependent and reversible.

Common Side Effects: - Nausea - Abdominal pain - Diarrhoea - Injection site erythema - Headache - Flushing

Serious or Rare Side Effects: - Gallbladder sludge or gallstones - Hyperglycaemia or hypoglycaemia - Brady‑t  t t t  g     

Octreotide should be used cautiously ;  the  c  …  t…  ewline

t  ewline  ewline  ewline ... ...